Skip to main content
logo
Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London flag London · Delayed Price · Currency is GBP · Price in USD
433.22
+3.11 (0.72%)
At close: Aug 13, 2025

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202012 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2012 - 2019
Other - Collaboration Revenue (Pre-FY2023)
-
Log In
Log In
Log In
Log In
Upgrade
Other - Collaboration Revenue (Pre-FY2023) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Total Collaboration
510.22M
Log In
Log In
Log In
Log In
Upgrade
Total Collaboration Growth
-21.87%
Log In
Log In
Log In
Log In
Upgrade
Novartis AG - Collaboration
79.76M
Log In
Log In
Log In
Log In
Upgrade
Novartis AG - Collaboration Growth
-
Log In
Log In
Log In
Log In
Upgrade
Vir Biotechnology - Collaboration
-
Log In
Log In
Log In
Log In
Upgrade
Vir Biotechnology - Collaboration Growth
-
Log In
Log In
Log In
Log In
Upgrade
ONPATTRO
252.86M
Log In
Log In
Log In
Log In
Upgrade
ONPATTRO Growth
-27.44%
Log In
Log In
Log In
Log In
Upgrade
GIVLAARI
255.87M
Log In
Log In
Log In
Log In
Upgrade
GIVLAARI Growth
15.42%
Log In
Log In
Log In
Log In
Upgrade
Regeneron Pharmaceuticals - Collaboration
302.80M
Log In
Log In
Log In
Log In
Upgrade
Regeneron Pharmaceuticals - Collaboration Growth
204.99%
Log In
Log In
Log In
Log In
Upgrade
OXLUMO
167.05M
Log In
Log In
Log In
Log In
Upgrade
OXLUMO Growth
29.74%
Log In
Log In
Log In
Log In
Upgrade
Royalty
91.79M
Log In
Log In
Log In
Log In
Upgrade
Royalty Growth
140.50%
Log In
Log In
Log In
Log In
Upgrade
AMVUTTRA
970.45M
Log In
Log In
Log In
Log In
Upgrade
AMVUTTRA Growth
66.62%
Log In
Log In
Log In
Log In
Upgrade
Roche - Collaboration
119.49M
Log In
Log In
Log In
Log In
Upgrade